Last updated on February 2018

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia


Brief description of study

Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.

Detailed Study Description

We will give 50mg of dasatinib daily since the diagnosis for up to 6 months, for the first 2-4 weeks we will evaluate hematic biometry to registry hematic response, at months 3 and 6 a BCR/ABL PCR will be taken to evaluate molecular response.

Clinical Study Identifier: NCT03216070

Contact Investigators or Research Sites near you

Start Over

David Gomez-Almaguer, MD

Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer
Monterrey, Mexico
  Connect »